Key facts
- This page summarizes Ola Soderquist's Form 4/A - Amendment filing for BIOXYTRAN, INC (BIXT).
- 3 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 18 Nov 2025, 13:12.
Ola Soderquist - 25 Oct 2024 Form 4/A - Amendment Insider Report for BIOXYTRAN, INC (BIXT)
- Reporting relationship
- CFO, 10%+ Owner
- Issuer ticker
- BIXT
- Reported as of
- 25 Oct 2024
- Net transaction value
- +$5,488,821
- SEC form
- 4/A - Amendment
- Accepted by SEC
- 18 Nov 2025, 13:12:20 UTC
- Original report date
- 25 Oct 2014
- Prior SEC filing
- 20 Aug 2024
- Source filing
- View source filing
- Reporting owner signature
- Ola Soderquist
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Ola Soderquist filed Form 4/A - Amendment for BIOXYTRAN, INC (BIXT) on 18 Nov 2025.
Change
- Previous filing in this sequence was filed on 20 Aug 2024.
- Current net transaction value: +$5,488,821.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4/A - Amendment disclosures.
Reporting Owners (1)
CIK 0001754429
Primary reporting owner
Soderquist Ola
- Relationship
- CFO, 10%+ Owner
- Address
- 47 HAMMOND STREET, UNIT 2, WALTHAM
- Signature
- Ola Soderquist
- Signature date
- 18 Nov 2025
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
BIXT
transaction
preferred
Other
- Transaction value
- $5,487,821
- Shares
- +10,069,396
- Change %
- +258%
- Price
- $0.5450
- Shares after
- 13,976,456
- Date
- 25 Oct 2024
- Ownership
- Direct
- Footnotes
- F1
BIXT
transaction
preferred
Other
- Transaction value
- $500
- Shares
- +100,000
- Change %
- +0.73%
- Price
- $0.005000
- Shares after
- 13,876,456
- Date
- 25 Oct 2024
- Ownership
- Direct
- Footnotes
- F2
BIXT
transaction
common
Other
- Transaction value
- $500
- Shares
- +500,000
- Change %
- Price
- $0.001000
- Shares after
- 500,000
- Date
- 25 Oct 2024
- Ownership
- Direct
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The Shares were issued as payment for the sale of NDPD Pharma to Bioxytran
Footnote F2
A 1:5 exchange of Preferred Stock (earlier issued under section 16b-3) into shares of Common Stock.